Granulocyte colony-stimulating factor in traumatic spinal cord injury.

Abstract

Granulocyte colony-stimulating factor (G-CSF) is a cytokine used in pharmaceutical preparations for the treatment of chemotherapy-induced neutropenia. Evidence from experimental studies indicates that G-CSF exerts relevant activities in the central nervous system (CNS) in particular after lesions. In acute, subacute, and chronic CNS lesions, G-CSF appears to have strong anti-inflammatory, antiapoptotic, antioxidative, myelin-protective, and axon-regenerative activities. Additional effects result in the stimulation of angiogenesis and neurogenesis as well as in bone marrow stem cell mobilization to the CNS. There are emerging preclinical and clinical data indicating that G-CSF is a safe and effective drug for the treatment of acute and chronic traumatic spinal cord injury (tSCI), which we summarize in this review.

• Authors: Stephanie Aschauer-Wallner, Stefan Leis, Ulrich Bogdahn, Siw Johannesen, Sebastien Couillard-Despres, Ludwig Aigner
• Journal: Drug discovery today (Drug Discov Today) Vol. 26 Issue 7 Pg. 1642-1655 (07 2021) ISSN: 1878-5832 [Electronic] England
• PMID: 33781952 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Chemical References

• Granulocyte Colony-Stimulating Factor

Topics

• Animals
• Drug Repositioning
• Granulocyte Colony-Stimulating Factor (pharmacology, therapeutic use)
• Humans
• Spinal Cord Injuries (drug therapy, epidemiology)